PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us

Our offering

At Evolve, we provide specialised IP strategy services tailored to the unique needs of pharmaceutical and biotechnology companies at every stage of development. Our approach combines scientific expertise with commercial insight to deliver practical intellectual property solutions that drive business value. We understand that effective IP strategy must be both deeply rooted in the science and adapt alongside your company’s growth.

With extensive industry experience and technical knowledge, we are passionate about supporting our clients to realise the full potential of their innovations.

 

Find out more

Evolve IP is able to offer commercially focused, strategic, and clear advice on complex patent portfolios

The team are thoughtful and intuitive and provide a personable service.

Evolve are friendly and knowledgeable and provide practical advice.

I chose Evolve because they have unique expertise in pharma IP. They are friendly and knowledgeable and provide practical advice.

I recommend Evolve for chemical/pharma patent issues – whether prosecution or complex FTO or loss of exclusivity considerations.

Evolve Intellectual Property offers expertise in patent portfolio management, strategic planning and formalities.

Evolve Intellectual Property is a growing firm, with an excellent reputation.

Evolve is a refreshing change to the traditional patent attorney form approach – much more nimble and responsive.

Fractional in-house

Do you need experienced IP leadership without the overhead of a full-time in-house team?

Our fractional in-house service delivers the senior head of IP expertise you require on a flexible and cost-effective basis, allowing you to scale your IP function precisely when and how you need it. We understand the critical role intellectual property plays in your growth and offer a tailored approach to align your IP strategy directly with your overarching business objectives. Our fractional in-house service seamlessly integrates with your existing team, becoming a trusted partner in managing your day-to-day IP needs. By working with us you will benefit from strategically managed intellectual property helping you to foster innovation, secure investment and gain a competitive edge.

With Evolve you access experienced IP leadership when you need it. Think of us as your dedicated, senior IP resource, readily available to handle the operational complexities while providing expert strategic direction.

Find out more

Sectors

Our team’s combined experience spans traditional pharmaceuticals to cutting-edge advanced therapies, providing you with guidance that is both scientifically informed and commercially pragmatic.

 

Find out more
  • Pharmaceuticals
  • Biotech
  • Biologics
  • Cell & gene therapy
  • AI drug discovery
  • Chemistry

Insights

Visit Evolve Insights for our latest articles and webinars on key emerging trends and strategic considerations in pharmaceutical IP.

Read more

Is AI software for IP just expensive wrapping paper?

  • 14th May 2026
At the last count, there were more than seventy companies offering AI-assisted IP software solutions. Most of these companies are less than two years old.

Are AI-generated materials legally privileged? United States v. Heppner

  • 13th May 2026
Legal privilege ensures that you can share sensitive information with your lawyers without fear of it being used against you in court. This protection is critical in all fields of law. In patent law, without the assurance of secrecy, the ability of a patentee or a defendant to receive candid advice would be severely diminished.…

The future of the patent profession: Are we looking into an AI abyss?

  • 8th May 2026
AI presents a huge dilemma for patent attorneys. There is no doubt that AI will have a dramatic impact on the profession and the business model that many firms have relied on for decades.

BREAKING: Imminent new referral to the EBA on the relevance of G1/24 to added matter

  • 6th May 2026
The Board of Appeal in T 873/24 has decided to refer questions to the Enlarged Board of Appeal (EBA) on the application of G1/24 (claim interpretation) to the assessment of added matter.

Use of AI in the patent industry: Are you behind the wheel or waiting for the bus?

  • 1st May 2026
It took a global pandemic to move some patent firms away from paper files. Today, it seems that patent attorneys are finally entering modernity with the growing adoption in the industry of automation tools for patent drafting and prosecution case management. Interestingly, much of this is being sold and promoted as “AI”, despite much of…

Description amendments can extend protection (T 439/22)

  • 3rd April 2026
The comments space for the last IPKat article on claim interpretation/description amendments appears to have maxed out. Sorry everyone, but maybe it’s for the best. However, fear not, we now have a new decision to restart the debate!

Our team

Evolve is a pharmaceutical specialist IP firm, offering comprehensive intellectual property services built on the experience of our attorneys in both in-house and private practice settings. Evolve is built on the deep expertise of our qualified attorneys in the pharmaceutical and biotech sector. With our personalized approach, scientific backgrounds and industry insights, we deliver tailored and pragmatic IP solutions for our pharmaceutical and biotechnology clients.

Meet the team

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

Subscribe

Contact Us